Frontier Biotechnologies Balance Sheet Health
Financial Health criteria checks 5/6
Frontier Biotechnologies has a total shareholder equity of CN¥1.3B and total debt of CN¥394.6M, which brings its debt-to-equity ratio to 30.7%. Its total assets and total liabilities are CN¥2.1B and CN¥796.6M respectively.
Key information
30.7%
Debt to equity ratio
CN¥394.62m
Debt
Interest coverage ratio | n/a |
Cash | CN¥899.22m |
Equity | CN¥1.29b |
Total liabilities | CN¥796.57m |
Total assets | CN¥2.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688221's short term assets (CN¥1.0B) exceed its short term liabilities (CN¥346.8M).
Long Term Liabilities: 688221's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥449.8M).
Debt to Equity History and Analysis
Debt Level: 688221 has more cash than its total debt.
Reducing Debt: 688221's debt to equity ratio has increased from 1.7% to 30.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688221 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 688221 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 13.8% each year.